EichorEICHOR
Location: Frankston Synced from ClinicalTrials.gov · August 08, 2026

Clinical studies recruiting near Frankston

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Novel Treatment Delivery of ECAP-controlled Closed-loop SCS for Chronic Pain
NA · Frankston Pain Management · Saluda Medical Pty Ltd · NCT04662905
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · Frankston Hospital-Oncology and Haematology ( Site 2704) · Merck Sharp & Dohme LLC · NCT06393374
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Co
Phase 1 · Peninsula & South Eastern Haematology and Oncology Group · Antengene Therapeutics Limited · NCT05205109
IKS014 in Advanced Solid Tumors That Express HER2
Phase 1 · Peninsula & South Eastern Haematology and Oncology Group (PS · Iksuda Therapeutics Ltd. · NCT05872295
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Mal
Phase 1 · Peninsula and South Eastern Haematology & Oncology Group · Shandong Suncadia Medicine Co., Ltd. · NCT06770569
Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS
Phase N/A · Peninsula Health · Monash University · NCT05180942
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alon
Phase 1/Phase 2 · Peninsula and South Eastern Haematology & Oncology Group · BioNTech SE · NCT07070232
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Phase 1/Phase 2 · PASO Medical · Eikon Therapeutics · NCT06907043
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Phase 1 · Peninsula & South Eastern Hematology and Oncology Group (PAS · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06343402
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Phase 2 · Frankston Hospital · Canadian Cancer Trials Group · NCT05640999
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · PASO Medical · ABL Bio, Inc. · NCT07158918
Safety and Efficacy of HB-1 for Post-Traumatic Stress Disorder
Phase 2 · Peninsula Therapeutic and Research Group · HB BioTech, LLC · NCT07499440
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/Phase 2 · Peninsula & South Eastern Haematology and Oncology Group · Hummingbird Bioscience · NCT05910827
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Tr
Phase 3 · Frankston Hospital-Oncology and Haematology ( Site 2003) · Merck Sharp & Dohme LLC · NCT06312176
Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced
Phase 1/Phase 2 · Peninsula & South Eastern Haematology & Oncology Group · Domain Therapeutics Australia Pty Ltd · NCT06819735
A Study of LM-350 in Subjects With Advanced Solid Tumours
Phase 1/Phase 2 · Peninsula and South Eastern Haematology and Oncology Group · LaNova Medicines Limited · NCT07112222
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Phase N/A · Frankston Hospital · Peninsula Health · NCT06321497
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Phase 1 · Peninsula and South Eastern Haematology and Oncology Group ( · Adcendo ApS · NCT06597721
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembroliz
Phase 1/Phase 2 · Peninsula & South Eastern Haematology and Oncology Group · ImmVira Pharma Co. Ltd · NCT04370587
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLI
Phase 1/Phase 2 · Peninsula and South Eastern Haematology & Oncology Group (PA · Jiangsu HengRui Medicine Co., Ltd. · NCT05277168
Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis
Phase 3 · Frankston Hospital - Peninsula Health · The George Institute · NCT05752279
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specifi
Phase 1 · Peninsula and Southeast Oncology · Bayer · NCT06659341
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Phase 3 · Research Site · AstraZeneca · NCT06307652
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Phase 3 · Peninsula Health · Boehringer Ingelheim · NCT06872892
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for L
Phase 2/Phase 3 · Peninsula & South Eastern Haematology and Oncology Group · BioNTech SE · NCT06712316
Randomised Evaluation of Sodium Dialysate Levels on Vascular Events
Phase 4 · Peninsula Health · University of Sydney · NCT02823821
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Phase 1/Phase 2 · Peninsula and South Eastern Haematology & Oncology Group · Incyclix Bio · NCT05735080
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Phase 1/Phase 2 · Peninsula Health-Frankston Hospital · Hoffmann-La Roche · NCT04802759
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated S
Phase 3 · Peninsula & South Eastern Haematology and Oncology Group · BioNTech SE · NCT06712355
Look up another city
Look up another condition